Tesic N - Search Results

1

Post-radiation xerostomia therapy with allogeneic mesenchymal stromal stem cells in patients with head and neck cancer: study protocol for phase I clinical trial.

Strojan P, Plavc G, Kokalj M, Mitrovic G, Blatnik O, Lezaic L, Socan A, Bavec A, Tesic N, Hartman K, Svajger U. Strojan P, et al. Among authors: tesic n. Radiol Oncol. 2023 Nov 30;57(4):538-549. doi: 10.2478/raon-2023-0052. eCollection 2023 Dec 1. Radiol Oncol. 2023. PMID: 38038413 Free PMC article.

2

Overview of Cellular Immunotherapies within Transfusion Medicine for the Treatment of Malignant Diseases.

Tešić N, Poženel P, Švajger U. Tešić N, et al. Int J Mol Sci. 2021 May 12;22(10):5120. doi: 10.3390/ijms22105120. Int J Mol Sci. 2021. PMID: 34066067 Free PMC article. Review.

3

Programmed death ligand 1 (PD-L1) plays a vital part in DC tolerogenicity induced by IFN-γ.

Švajger U, Tešić N, Rožman P. Švajger U, et al. Among authors: tesic n. Int Immunopharmacol. 2021 Oct;99:107978. doi: 10.1016/j.intimp.2021.107978. Epub 2021 Jul 20. Int Immunopharmacol. 2021. PMID: 34298399

4

Combined TLR-3/TLR-8 Signaling in the Presence of α-Type-1 Cytokines Represents a Novel and Potent Dendritic Cell Type-1, Anti-Cancer Maturation Protocol.

Fevžer T, Poženel P, Zajc K, Tešić N, Švajger U. Fevžer T, et al. Among authors: tesic n. Cells. 2022 Feb 28;11(5):835. doi: 10.3390/cells11050835. Cells. 2022. PMID: 35269457 Free PMC article.

5

Dendritic Cells Generated in the Presence of Platelet Lysate Have a Reduced Type 1 Polarization Capacity.

Tešić N, Pekle Simonič I, Roškar K, Rožman P, Švajger U. Tešić N, et al. Immunol Invest. 2020 Apr;49(3):215-231. doi: 10.1080/08820139.2019.1624768. Epub 2019 Jun 7. Immunol Invest. 2020. PMID: 31170833

6

Efficacy and safety of electrochemotherapy combined with peritumoral IL-12 gene electrotransfer of canine mast cell tumours.

Cemazar M, Ambrozic Avgustin J, Pavlin D, Sersa G, Poli A, Krhac Levacic A, Tesic N, Lampreht Tratar U, Rak M, Tozon N. Cemazar M, et al. Among authors: tesic n. Vet Comp Oncol. 2017 Jun;15(2):641-654. doi: 10.1111/vco.12208. Epub 2016 Feb 3. Vet Comp Oncol. 2017. PMID: 26840222 Clinical Trial.

7

Improved Specificity of Gene Electrotransfer to Skin Using pDNA Under the Control of Collagen Tissue-Specific Promoter.

Kos S, Tesic N, Kamensek U, Blagus T, Cemazar M, Kranjc S, Lavrencak J, Sersa G. Kos S, et al. Among authors: tesic n. J Membr Biol. 2015 Oct;248(5):919-28. doi: 10.1007/s00232-015-9799-4. Epub 2015 Apr 4. J Membr Biol. 2015. PMID: 25840832

8

Clinically Usable Interleukin 12 Plasmid without an Antibiotic Resistance Gene: Functionality and Toxicity Study in Murine Melanoma Model.

Kamensek U, Tesic N, Sersa G, Cemazar M. Kamensek U, et al. Among authors: tesic n. Cancers (Basel). 2018 Feb 27;10(3):60. doi: 10.3390/cancers10030060. Cancers (Basel). 2018. PMID: 29495490 Free PMC article.

9

Endoglin (CD105) Silencing Mediated by shRNA Under the Control of Endothelin-1 Promoter for Targeted Gene Therapy of Melanoma.

Tesic N, Kamensek U, Sersa G, Kranjc S, Stimac M, Lampreht U, Preat V, Vandermeulen G, Butinar M, Turk B, Cemazar M. Tesic N, et al. Mol Ther Nucleic Acids. 2015 May 5;4:e239. doi: 10.1038/mtna.2015.12. Mol Ther Nucleic Acids. 2015. PMID: 25942402 Free article.

10

Tailor-made fibroblast-specific and antibiotic-free interleukin 12 plasmid for gene electrotransfer-mediated cancer immunotherapy.

Kamensek U, Tesic N, Sersa G, Kos S, Cemazar M. Kamensek U, et al. Among authors: tesic n. Plasmid. 2017 Jan;89:9-15. doi: 10.1016/j.plasmid.2016.11.004. Epub 2016 Nov 24. Plasmid. 2017. PMID: 27890562

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

13 results

Search Page

Filters